300122SZSE
🚨 Material Event

Announcement on Obtaining Drug Registration Certificate for Self-Developed Product Liraglutide Injection

✨ AI Summary

Chongqing Zhifei Biological Products Co., Ltd. announces its subsidiary has obtained a drug registration certificate for Liraglutide Injection. This product is for type 2 diabetes treatment and cardiovascular risk reduction. This approval is a key step in the company's metabolic disease strategy, expanding its product pipeline and market presence.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Chongqing Zhifei Biological Products Co., Ltd.

Announcement on Obtaining Drug Registration Certificate for Self-Developed Product Liraglutide Injection

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.

Chongqing Zhifei Biological Products Co., Ltd. (hereinafter referred to as the "Company") recently learned that its holding subsidiary, Chongqing Chengan Biopharmaceutical Co., Ltd. (hereinafter referred to as "Chengan Biopharmaceutical"), has obtained the "Drug Registration Certificate" for Liraglutide Injection issued by the National Medical Products Administration. The relevant situation is hereby announced as follows:

I. Basic Information of the Drug

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.